(AOF) – Mauna Kea Technologies announced a 74% increase in its revenues over the first 9 months of 2023. A solid performance for the inventor of Cellvizio, the multidisciplinary platform for confocal laser endomicroscopy by probe and by needle, enabled thanks to partnership revenues and growth in the United States (+40%).
“This third quarter was once again positive after a solid second quarter, a performance which reflects our commercial and business development dynamics. Indeed, the Group benefited from its partnership strategy, which generated more than 30% of the turnover. business, and we continue to see exciting opportunities to increase the number of partners marketing Cellvizio,” said Mauna Kea Technologies management.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.